Wordt geladen...
New therapies for von Willebrand disease
The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C), due to the loss of binding and stabilization by...
Bewaard in:
| Gepubliceerd in: | Blood Adv |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6855108/ https://ncbi.nlm.nih.gov/pubmed/31714963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000368 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|